Fig. 7: Oxa12 decreases zVAD-fmk-induced JNK and p38 MAPK activation in BV2 cells.
From: Phenotypic screening identifies a new oxazolone inhibitor of necroptosis and neuroinflammation
BV2 cells were treated with zVAD-fmk (25 µM) in the presence or absence of Nec-1 (30 µM) or Oxa12 (30 µM) for 24 h. Representative immunoblots are presented, together with the respective densitometric analysis of the p-JNK/JNK, p-p38/p38 and p-Akt/Akt ratios. a p-JNK (Thr183/Tyr185) and total JNK. b p-p38 (Thr180/Tyr182) and total p38. c p-Akt (Ser473) and total Akt. Results are expressed as mean ± SEM of three independent experiments. *p < 0.001 vs. control; ǂp < 0.05 vs. zVAD-fmk; Ɨp < 0.01 vs. control; §p < 0.001 vs. zVAD-fmk
